Last reviewed · How we verify

NCT06066866

Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment

Not yet recruiting Last updated 6 October 2023
What this trial tests

trial testing endoscopic sampling of luminal fluid in Healthy in 150 participants. Not yet recruiting.

Timeline
1 January 2024
Primary endpoint
1 January 2026
1 January 2028

Quick facts

Lead sponsorStanford University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment150
Start date1 January 2024
Primary completion1 January 2026
Estimated completion1 January 2028

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 100, any sex, with Healthy or IBS - Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06066866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing